Your browser doesn't support javascript.
loading
A scalable pipeline for SARS-CoV-2 replicon construction based on de-novo synthesis
Ahmet Can Berkyurek; Elian Lee; Omer Weissbrod; Roni Rasnic; Ilaria Falciatori; Siyuan Chen; Yaniv Erlich.
Afiliação
  • Ahmet Can Berkyurek; Eleven Therapeutics
  • Elian Lee; Twist Bioscience
  • Omer Weissbrod; Eleven Therapeutics
  • Roni Rasnic; Eleven Therapeutics
  • Ilaria Falciatori; Eleven Therapeutics
  • Siyuan Chen; Twist Bioscience
  • Yaniv Erlich; Eleven Therapeutics
Preprint em En | PREPRINT-BIORXIV | ID: ppbiorxiv-478644
ABSTRACT
Replicons are synthetic viral RNA molecules that recapitulate the self-replicating activities of the virus but are missing its infectivity potential. Here, we report on a scalable pipeline to generate a replicon of any SARS-CoV-2 strain using de-novo synthesis. Our pipeline relies only on publicly available sequencing data without requiring access to any material, simplifying logistical and bureaucratic issues of sample acquisition. In addition, our system retains the nucleotide sequence of most of the SARS-CoV-2 full genome and therefore better captures its underlying genomic and biological functions as compared to the popular pseudotypes or any replicon system published to-date. We utilized our system to synthesize a SARS-CoV-2 non-infectious version of the Beta strain. We then confirmed that the resulting RNA molecules are non-infectious and safe to handle in a BSL2/CL2 facility. Finally, we show that our replicon can be specifically inhibited by molnupiravir and RNAi treatments, demonstrating its utility for drug research and development.
Licença
cc_by_nc_nd
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-BIORXIV Idioma: En Ano de publicação: 2022 Tipo de documento: Preprint
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-BIORXIV Idioma: En Ano de publicação: 2022 Tipo de documento: Preprint
...